Trial Outcomes & Findings for HIV and Fat Accumulation (NCT NCT01088295)

Results Overview

VAT volume was quantified at each timepoint by L4-L5 single slice computed tomography

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

35 participants

Primary outcome timeframe

Baseline and 24 weeks

Results posted on

2019-02-04

Subjects were recruited between May and October 2010 at the UCLA CARE Center.

Participant milestones
Measure	Telmisartan Telmisartan 40mg po daily for 24 weeks
Overall Study STARTED	36
Overall Study COMPLETED	35
Overall Study NOT COMPLETED	1

Withdrawal data not reported

HIV and Fat Accumulation

Baseline characteristics by cohort
Measure	Telmisartan n=36 Participants Telmisartan 40mg po daily for 24 weeks
Age, Categorical <=18 years	0 Participants n=5 Participants
Age, Categorical Between 18 and 65 years	36 Participants n=5 Participants
Age, Categorical >=65 years	0 Participants n=5 Participants
Age, Continuous	49 years STANDARD_DEVIATION 7.4 • n=5 Participants
Sex: Female, Male Female	16 Participants n=5 Participants
Sex: Female, Male Male	20 Participants n=5 Participants
Region of Enrollment United States	36 participants n=5 Participants

Timeframe: Baseline and 24 weeks

Population: as-treated analysis

VAT volume was quantified at each timepoint by L4-L5 single slice computed tomography

Outcome measures
Measure	Telmisartan n=35 Participants Telmisartan 40mg po daily for 24 weeks
Median Change in Visceral Adipose Tissue (VAT) Volume	-4.6 cm^2 Interval -29.5 to 31.2

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Adverse event data not reported

Adverse event data not reported

University of California, Los Angeles

Phone: (310)557-1891